Navigation Links
Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
Date:9/24/2007

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008

WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, an independent Data Monitoring Committee (DMC) completed an interim analysis of the safety data from the first 35 evaluable patients and recommended that the trial continue per the protocol. No major safety concerns were identified by the DMC.

In accordance with the trial protocol, the DMC will conduct another interim analysis of safety data from the first 65 evaluable patients. The Company expects to report the outcome of the 65-patient safety analysis by the end of 2007. Additionally, the Company now expects to complete enrollment in the PROPEL trial in the second quarter of 2008.

"The outcomes of these interim analyses represent continued progress toward the completion of the PROPEL trial and an important milestone in the development of a potential new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "We are pleased with the progress of the PROPEL trial and look forward to completing enrollment in the second quarter
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... , March 17 Micromet, Inc. (Nasdaq: MITI ) announced ... underwriters exercised in full their option to purchase an additional 1.5 million shares of ... its common stock at a public offering price of $7.00 per share. ... ... ...
(Date:3/17/2010)... LAKE MARY, Fla. , March 17 Access MediQuip, LLC, ... to the healthcare industry, announced today it has enhanced its proprietary Recall Management ... patients, inform and empower surgeons and facilities, and help payers improve quality while ... ... ...
(Date:3/17/2010)... Sermo ( http://www.sermo.com ), ... today announced the results of a new ... Physicians Social Media Conversations. " The report ... about blood clotting, anticoagulation, anti-platelet, and thrombolytic ... highly anticipate Xarelto (Bayer/ Johnson & Johnson), ...
Breaking Medicine Technology:Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 2Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 3Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point 2Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point 3Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point 4NAMI Observes Minority Mental Health Awareness Month 50527 1NAMI Observes Minority Mental Health Awareness Month 50527 2Finally The Round Diet 21 A Diet Simple Enough that Even a Kindergartener Can Follow It 50523 1Finally The Round Diet 21 A Diet Simple Enough that Even a Kindergartener Can Follow It 50523 2Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 1Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 2Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 3Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 4Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 5
... 0in 0in 0pt; LINE-HEIGHT: 150%; mso-hyphenate: none">,BUDAPEST, ... stop thousands of patients with cancer from ... the 10th Congress of,the European Association for ... whether this first in class novel,formulation could ...
... of European Hematology -, CHESHIRE, Conn., June ... announced results from three analyses,of Phase III ... paroxysmal nocturnal hemoglobinuria (PNH) at the 12th,Congress ... Association (EHA) in Vienna. These presentations,included: , ...
Other Medicine Technology:Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7
(Date:3/18/2010)... provide a Consumer Alert Center with information about defective products, ... to ForThePeople.com can stay up to date on the latest ... ... (PRWEB) March 18, 2010 -- Morgan and Morgan ... have been injured by dangerous and defective products. In order ...
(Date:3/17/2010)... ... , ... ... ... a new online survey conducted in February on its behalf by Harris Interactive ® , which illustrates how heavily online women(1) rely on the Internet as ...
(Date:3/17/2010)... A recent study organized by Stanford University researchers found ... a reduction in seizures after deep brain stimulation. ... stimulation of the anterior nuclei of thalamus for epilepsy ... 56% reduction in seizure frequency. Full findings of ... , a journal published by Wiley-Blackwell on behalf of ...
(Date:3/17/2010)... -- Feeding America President and CEO, Vicki Escarra , today issued the following statement regarding the Reauthorization of the Child Nutrition Act: ... ... ... ... "On behalf of Feeding America and its more ...
(Date:3/17/2010)... March 17 Centene Corporation (NYSE: CNC ) announced today that one of its subsidiaries, Cenpatico Behavioral Health of Arizona ... ... , , ... ... ...
Breaking Medicine News(10 mins):Health News:Morgan and Morgan Provides Consumer Alert Center with Information about Dangerous Products 2Health News:New iVillage Study Reveals That Majority of Women 18-34 Go Online First With Health Questions - Before Turning to Their Doctor or Other Family Members 2Health News:New iVillage Study Reveals That Majority of Women 18-34 Go Online First With Health Questions - Before Turning to Their Doctor or Other Family Members 3Health News:New iVillage Study Reveals That Majority of Women 18-34 Go Online First With Health Questions - Before Turning to Their Doctor or Other Family Members 4Health News:New iVillage Study Reveals That Majority of Women 18-34 Go Online First With Health Questions - Before Turning to Their Doctor or Other Family Members 5Health News:New iVillage Study Reveals That Majority of Women 18-34 Go Online First With Health Questions - Before Turning to Their Doctor or Other Family Members 6Health News:Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures 2Health News:Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures 3Health News:Statement from Vicki Escarra, President and CEO, Feeding America, on the Child Nutrition Reauthorization Draft Legislative Proposal 2Health News:Statement from Vicki Escarra, President and CEO, Feeding America, on the Child Nutrition Reauthorization Draft Legislative Proposal 3Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 2Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 3Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 4
... understanding of the incurable neurological disorder , , FRIDAY, March ... GIGYF2 may be directly linked to the development of ... neurodegenerative condition, U.S. researchers report. , "These findings may ... new therapeutic -- and possibly even preventive -- strategies ...
... ORLANDO, Fla., March 21 MEDai, Inc., headquartered ... for healthcare that,utilize award-winning predictive analytics, has been ... the benefits of predictive modeling.,At the upcoming World ... MEDai will present a general session and,workshop that ...
... 2010 Will Top 20% Changes Threaten Beneficiary Services, ... ... Leaders in the home,oxygen community today expressed concern over Centers ... Medicare,s competitive bidding program for the home oxygen therapy,benefit., The ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") ... -- Senior Housing Development and Operations, has resigned ... the senior,living business., "We are grateful to ... past year, especially with the very successful integration ...
... tocilizumab lies in head-to-head drug trials, expert says , , ... drug tocilizumab, now being tested, appears to be effective ... adults and children, according to the results of two ... interleukin-6 receptor. Interleukin-6 is a molecule involved in promoting ...
... (Nasdaq:,CRYO), a medical device company focused on the treatment ... the year ended,December 31, 2007. CryoCor reported a net ... year ended December 31, 2007, as compared to a ... the year ended December 31,2006. CryoCor reported that it ...
Other Medicine News:Health News:Gene Linked to Form of Parkinson's Disease 2Health News:MEDai Assists Healthcare Organizations Demonstrate the Value of Predictive Modeling 2Health News:Home Oxygen Leaders Warn That Competitive Bidding Program Reductions Combined with Other Pending and Proposed Cuts Are 'Unsustainable and Unpredictable' 2Health News:Ventas Announces Brush Departure 2Health News:Ventas Announces Brush Departure 3Health News:Ventas Announces Brush Departure 4Health News:New Rheumatoid Arthritis Drug Works for Adults, Children 2Health News:New Rheumatoid Arthritis Drug Works for Adults, Children 3Health News:CryoCor Reports 2007 Results 2Health News:CryoCor Reports 2007 Results 3Health News:CryoCor Reports 2007 Results 4Health News:CryoCor Reports 2007 Results 5Health News:CryoCor Reports 2007 Results 6Health News:CryoCor Reports 2007 Results 7Health News:CryoCor Reports 2007 Results 8
Large, bright images from a bronchoscope designed for routine examination and treatment....
... The BF-P40, the first in a ... the design and features necessary to meet ... treatment capabilities. The scope includes a new ... increased operator comfort. It also provides a ...
... Double lumen ... one-lung ventilation., ... Tube is packaged ... tube-to-circuit adaptors, suction ...
... Used for endobronchial ... or right lung for ... ventilation. The set consists ... catheter and an Arndt ...
Medicine Products: